IQVIA Launches a Transformative Suite of Virtual Research Solutions

IQVIA (NYSE:IQV) announced today the launch of Virtual Research Solutions, a new suite of technology-led study options offering advances in patient-centric trial design and execution.

Powered by the IQVIA CORE™, Virtual Research Solutions brings together unparalleled information assets, advanced analytics, technologies and critical domain expertise to design and execute trials and late-phase studies with people in mind. It starts with smart, connected devices and remote-monitoring systems that are linked to a dedicated virtual network of investigators and local healthcare providers. The suite of solutions leverages IQVIA’s global resources and expertise in a secure, cloud-based platform designed to help accelerate research with a keen focus on protecting privacy and reducing risk. IQVIA’s Virtual Research Solutions is enabled by a range of complementary applications, including eConsent™ for online enrollment, AppScript™ to support digital patient engagement and the IQVIA Study Hub™, a virtual research technology platform designed to coordinate research and workflows, support patient communications, and seamlessly capture study activity throughout the patient journey.

IQVIA’s investment strategy for accelerating innovation has been to bring together deep scientific expertise and an expanding technology portfolio to disrupt clinical development and real-world evidence generation models through the use of predictive analytic algorithms, artificial intelligence (AI) tools, and an integrated technology architecture. The result is a more human, and more humane, approach to research that can now be designed to proactively address common issues from the beginning while also achieving the two critical objectives of maintaining the scientific rigor required to meet regulatory and compliance requirements, and avoiding costly delays.

IQVIA’s Virtual Research Solutions creates a patient-centric, decentralized alternative to traditional trial design and execution. It addresses those more complex research situations where patients cannot easily get to sites, where long-term safety studies may require years of follow-up, and where research with more patient-centric outcomes can be collected digitally. This set of solutions focuses on two critical areas – Virtual Trials for clinical development and Virtual Studies for real-world evidence outcomes. Unlike other emerging options in the market that are merely tweaking conventional approaches to research, IQVIA’s Virtual Research Solutions suite offers customers a fundamental new way to create and validate protocols leveraging IQVIA’s e360^TM technology and scientific experts across numerous therapy areas. These services, including IQVIA’s Centralized Monitoring solution, optimize delivery and reduce the uncertainty of study execution.

Richard Staub, president of IQVIA’s Research & Development Solutions, indicated that the time has come for such a reorientation, "IQVIA’s advances in technologies and analytics, combined with our expanding understanding of how the human experience informs human health, all point to an opportunity to rethink research in healthcare. For instance, significant distances between patients and investigators, heavy time commitments for research participants, low patient enrollment and high dropout rates are challenges researchers regularly face. Our virtual solution minimizes trial impact on patient lives, while maximizing patient and customer experience as well as the number and diversity of participants. It also improves the study’s value, evidence-generation, and health outcomes while delivering shorter trial startups and faster recruitment.”

"IQVIA’s Virtual Research Solutions is the catalyst we need to refocus our time, energy and resources on research that works,” said Jon Resnick, president, Real-World & Analytics Solutions, IQVIA. "Tapping into technology advances and our distinctive information infrastructure, we can start to provide proof of value and outcomes by understanding how treatments affect patients in their everyday lives. This is the real future of patient-centricity within real-world evidence.”

To find out more about the IQVIA Virtual Trial solution, visit https://www.iqvia.com/solutions/research-and-development/virtual-trials.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Click here to subscribe to Mobile Alerts for IQVIA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180621005361/en/